Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,127
  • Shares Outstanding, K 4,449
  • Annual Sales, $ 4,310 K
  • Annual Income, $ -17,750 K
  • 60-Month Beta 7.33
  • Price/Sales 27.55
  • Price/Cash Flow N/A
  • Price/Book 6.77
Trade APVO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -1.62
  • Number of Estimates 2
  • High Estimate -1.55
  • Low Estimate -1.69
  • Prior Year -2.42
  • Growth Rate Est. (year over year) +33.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.53 +6.20%
on 04/13/21
39.27 -36.36%
on 03/15/21
-10.98 (-30.53%)
since 03/12/21
3-Month
23.53 +6.20%
on 04/13/21
43.21 -42.17%
on 02/10/21
-9.09 (-26.67%)
since 01/13/21
52-Week
3.44 +627.30%
on 04/16/20
60.00 -58.35%
on 11/09/20
+21.25 (+567.95%)
since 04/13/20

Most Recent Stories

More News
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 24.99 (+1.67%)
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update

PFE : 37.16 (+0.51%)
APVO : 24.99 (+1.67%)
Aptevo Confirms Receipt of Nominations and Proposal Notice

Stockholders Are Not Required to Take Any Action at this Time

APVO : 24.99 (+1.67%)
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics...

APVO : 24.99 (+1.67%)
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 24.99 (+1.67%)
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442

New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform Technology

APVO : 24.99 (+1.67%)
Aptevo Confirms Receipt of Unsolicited Indication of Interest

SEATTLE, WA / ACCESSWIRE / November 19, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 24.99 (+1.67%)
Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, SOLO, AZN, CORT, and XXII.

XXII : 3.46 (-0.57%)
APVO : 24.99 (+1.67%)
AZN : 49.19 (-0.47%)
SOLO : 4.60 (+0.88%)
CORT : 22.28 (-0.67%)
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ --Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...

APVO : 24.99 (+1.67%)
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

and , /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics...

APVO : 24.99 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 26.94
2nd Resistance Point 25.96
1st Resistance Point 25.48
Last Price 24.99
1st Support Level 24.02
2nd Support Level 23.04
3rd Support Level 22.56

See More

52-Week High 60.00
Fibonacci 61.8% 38.39
Fibonacci 50% 31.72
Fibonacci 38.2% 25.04
Last Price 24.99
52-Week Low 3.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar